<DOC>
	<DOCNO>NCT02896803</DOCNO>
	<brief_summary>Patients locally advance metastatic pancreatic adenocarcinoma eligible infusional fluorouracil , irinotecan oxaliplatin ( FOLFIRINOX ) ( PPS 2 hyperbilirubinemia , among cause ) treat mFLOX regimen ( fluorouracil bolus oxaliplatin ) . The primary endpoint assess objective response rate accord RECIST criterion ( version 1.1 ) secondary endpoint time clinical radiological progression , overall survival , toxicity profile .</brief_summary>
	<brief_title>Fluorouracil Oxaliplatin First-line Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Currently , FOLFIRINOX consider standard treatment PS 0 1 patient advanced pancreatic carcinoma . However , due excessive toxicity dose reduction interruption treatment toxicity frequent . So , eligible patient ( PS 2 3 , hyperbilirubinemia , among cause ) , alternative scheme gemcitabine alone standard approach . This study aim evaluate efficacy safety mFLOX regimen ( fluorouracil bolus oxaliplatin ) first-line regimen advance pancreatic adenocarcinoma eligible FOLFIRINOX . The primary endpoint assess objective response rate accord RECIST criterion ( version 1.1 ) secondary endpoint time clinical radiological progression , overall survival , toxicity profile . It estimate n=34 response rate 20 % , compare historical control 7 % gemcitabine alone ( Von Hoff et al . ) , alpha error 5 % power 80 % . Considering rate 10 % dropout , sample 37 patient .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients pancreatic adenocarcinoma , confirm biopsy histological material available review Unresectable primary tumor consider team assistant metastatic disease Aged 18 75 time study entry Naïve patient palliative chemotherapy , admit treatment Institute São Paulo State Cancer ( ICESP ) Patients performance status 0 1 , candidate receive chemotherapy FOLFIRINOX performance status 2 . No significant organ dysfunction define : Hb &gt; 9 g / dL , platelet &gt; 100,000 / microliter ( mcL ) , neutrophils &gt; 1500 / mcL , clearance creatinine ( ClCr ) &gt; 50 ml / min , total bilirubin &lt; 5 mg/dl , serum alanine transaminase ( ALT ) aspartate transaminase ( AST ) &lt; 2.5 x upper limit normal ( ULN ) ( &lt; 5 x ULN liver metastasis present ) Able read sign inform consent form . Use prior chemotherapy agent , except adjuvant chemotherapy gemcitabine monotherapy since complete 6 month Absence histological material available local review ( eg diagnostic fine needle aspiration ( FNA ) cytology ) Previous use radiotherapy primary tumor metastasis site serve target lesion assess response treatment Diagnosis malignancy activity except nonmelanoma skin cancer Clinical evidence metastasis central nervous system active meningeal carcinomatosis severe chronic disease patient ( cirrhosis , heart failure New York Heart Association Functional Classification ( NYHA ) III IV , chronic obstructive pulmonary disease ( COPD ) oxygendependent chronic kidney disease require dialysis ) Pregnant breastfeed Patients HIV / AIDS story antiretroviral therapy Patients peripheral neuropathy grade &gt; 2 ( CTCAE v4.03 ) Medium large surgery last 4 week . For example , biliary derivation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>